1. Prevalence of Glucose-6-Phosphate Dehydrogenase Deficiency and Gametocytemia in a Pre-Elimination, Low Malaria Transmission Setting in Southern Zambia.
- Author
-
Kobayashi T, Kurani S, Hamapumbu H, Stevenson JC, Thuma PE, and Moss WJ
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Female, Germ Cells microbiology, Glucosephosphate Dehydrogenase Deficiency epidemiology, Humans, Infant, Infant, Newborn, Malaria epidemiology, Male, Prevalence, Young Adult, Zambia epidemiology, Antimalarials therapeutic use, Gametogenesis drug effects, Glucosephosphate Dehydrogenase drug effects, Glucosephosphate Dehydrogenase Deficiency chemically induced, Malaria drug therapy, Malaria prevention & control, Malaria transmission, Primaquine therapeutic use
- Abstract
The WHO recommends single low-dose (SLD) primaquine as a gametocytocide to reduce Plasmodium falciparum transmission in areas of low transmission. Despite this recommendation, uptake of SLD primaquine has been low because of concerns of glucose-6-phosphate dehydrogenase (G6PD) deficiency. Individuals with G6PD deficiency can experience hemolysis when exposed to primaquine. In Southern Province, Zambia, malaria transmission has declined significantly over the past decade. Single low-dose primaquine may be an effective tool, but there is limited information on G6PD deficiency. We screened 137 residents in Macha, Southern Province, Zambia, and the prevalence of G6PD (A-) was 15%. We also revisited data collected from 2008 to 2013 in the same area and found the highest gametocyte burden among those aged 5-15 years. The findings from this study suggest that SLD primaquine targeted to school-aged children may be an effective tool to help achieve malaria elimination in southern Zambia.
- Published
- 2021
- Full Text
- View/download PDF